Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 38, Issue 5, 1997, Pages 941-947

  Sartor, Carolyn I ^a,c   Strawderman, Myla H ^a   Lin, Xi Hong ^a   Kish, Katherine E ^a   McLaughlin, Patrick W ^b   Sandler, Howard M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Providence Cancer Center   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Local recurrence; Metastasis; Prostate cancer; Prostate specific antigen; PSA rise; Radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECURRENCE RISK; TREATMENT OUTCOME;

ADENOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 0030857412     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00082-5     Document Type: Article

References (32)

1. Agresti, A. Categorical data analysis. New York: John Wiley and Sons; 1990.
2. Ahlering, T. E.; Lieskovsky, G.; Skinner, D. Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J. Urol. 147:900-902; 1992.
3. Akaike, H. Fitting autoregressive models for prediction. Ann. of the Inst. of Stat. Mathematics 21:243; 1969.
4. American Cancer Society: 1994 Facts and Figures. Atlanta: American Cancer Society; 1994.
5. Catalona, W. Radical surgery for advanced prostate cancer and for radiation failures. J. Urol. 147:916; 1992.
6. Chodak, G. W.; Neumann, J.; Blix, G.; Sutton, H.; Farah, R. Effect of external beam radiation therapy on serum prostate-specific antigen. Urology 35:288-294; 1990.
7. Chodak, G. W.; Thisted, R. A.; Gerber, G. S.; Johansson, J.-E.; Adolfsson, J.; Jones, G. W.; Chisholm, G. D.; Moskovitz, B.; Livne, P. M.; Warner, J. Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med. 330:242-248; 1994.
8. D'Amico, A. V.; Hanks, G. E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72:2638-2643; 1993.
9. Goffinet, D. R.; Martinez, A.; Freiha, F.; Pooler, D.; Pistenma, D. A.; Cumes, D.; Bagshaw, M. 125-Iodine prostate implants for recurrent carcinomas after external beam irradiation: preliminary results. Cancer 45:2717-2724; 1980.
10. Hanks, G. E.; Asbell, S.; Krall, J. M.; Perez, C. A.; Doggett, S.; Rubin, P.; Sause, W.; Pilepich, M. V. Outcome for lymph node dissection negative T-1b, T-2 (A-2, B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int. J. Radiat. Oncol. Biol. Phys. 21:1099-1103; 1991.
11. Hanks, G. E.; D'Amico, A.; Epstein, B. E.; Schultheiss, T. E. Prostate specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int. J. Radiat. Oncol. Biol. Phys. 27:125-127; 1993.
12. Kaplan, I.; Cox, R.; Bagshaw, M. Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. J. Urol. 149:519-522; 1993.
13. Kavadi, V. S.; Zagars, G. K.; Pollack, A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int. J. Radiat. Oncol. Biol. Phys. 30:279-287; 1994.
14. Kuban, D. A.; El-Mahdi, A. M.; Schellhammer, P. F. Prostate-specific antigen for pretreatment prediction and post-treatment evaluation of outcome after definitive irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:307-316; 1995.
15. Lange, P. H.; Ercole, C. J.; Lightner, D. J.; Fraley, E. E.; Vessella, R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol. 141:873-879; 1989.
16. Lee, W. R.; Hanks, G. E.; Schultheiss, T. E.; Corn, B. J.; Hunt, M. A. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J. Clin. Oncol. 13:464-469; 1995.
17. Lerner, S. E.; Blute, M. L.; Zincke, H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J. Urology 154:1103-1103; 1995.
18. NIH Consensus Development Conference, June 15-17, 1987. The management of clinically localized prostate cancer. J. Urol. 138:1369-1375, 1987.
19. Partin, A. W.; Pound, C. R.; Pearson, J. D.; Clemens, J. Q.; Landis, P. K.; Epstein, J. I.; Carter, H. B.; Walsh, P. C. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43:649-659; 1994.
20. Paulson, D. F. Radiotherapy versus surgery for localized prostatic carcinoma. Urol. Clin. N. Am. 14:675-684; 1987.
21. Pisansky, T. M.; Cha, S. S.; Earle, J. D.; Durr, D.; Kozelsky, T. F.; Wieand, H. S.; Oesterling, J. E. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 11:2158-2166; 1993.
22. Russell, K. J.; Dunatov, C.; Hafermann, M. D.; Griffeth, J. T.; Polissar, L.; Pelton, J.; Cole, S. B.; Taylor, E. W.; Wiens, L. W.; Ko, W. J.; Austin-Seymour, M. M.; Griffin, B. R.; Russell, A. H.; Laramore, G. E.; Griffin, T. W. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J. Urol. 146:1046-1052; 1991.
23. Sandler, H. M.; McShan, D. L.; Lichter, A. S. Potential improvement in the results of irradiation for prostate carcinoma using improved dose distribution. Int. J. Radiat. Oncol. Biol. Phys. 22:361-367; 1992.
24. Sandler, H. M.; McLauglin, P. W.; Kish, K. E.; Lichter, A. S. Results of 3D conformal radiotherapy in the treatment of 707 patients with localized prostate cancer. (Abstr.) Int. J. Radiat. Oncol. Biol. Phys. 32:141; 1995.
25. Stamey, T. A.; Kabalin, J. N.; Ferrari, M. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J. Urol. 141:1084-1087; 1989.
26. Ten Haken, R. K.; Perez-Tamayo, C.; Tesser, R. J.; McShan, D. L.; Fraass, B. A.; Lichter, A. S. Boost treatment of the prostate using shaped, fixed fields. Int. J. Radiat. Oncol. Biol. Phys. 16:193-200; 1989.
27. Zagars, G. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 23:47-53; 1992.
28. Zagars, G.; Pollack, A. The fall and rise of prostate-specific antigen. Cancer 72:832-842; 1993.
29. Zagars, G. K.; Ayala, A. G.; vonEschenbach, A. C.; Pollack, A. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up of 648 patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 31:237-245; 1995.
30. Zagars, G. K.; Pollack, A.; Kavadi, V. S.; von Eschenbach, A. C. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:293-306; 1995.
31. Zeitman, A. L.; Coen, J. J.; Shipley, W. U.; Willet, C. G.; Efrid, J. T. Radical radiotherapy in the management of prostatic adenocarcinoma: the initial prostate-specific antigen value as a predictor of treatment outcome. J. Urology 151:640-645; 1994.
32. Zeitman, A. L.; Coen, J. J.; Dallow, K. C.; Shipley, W. U. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int. J. Radiat. Oncol. Biol. Phys. 32:287-292; 1995.